---
schema_version: "secwatch.filing_event.v1"
accession: "0001906324-23-000056"
form_type: "8-K"
ticker: "QDEL"
cik: "0001906324"
company_name: "QuidelOrtho Corp"
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T03:21:31.181285+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# QuidelOrtho Q3 revenue $744M, GAAP loss $0.19/sh, adj EPS $0.90; maintains FY guidance

## Summary
- Total revenue $744.0M, down from $783.8M YoY; respiratory revenue declined 21% as anticipated.
- GAAP net loss $(13)M, diluted loss per share $(0.19); adjusted diluted EPS $0.90 vs $1.85 prior year.
- Non-respiratory revenue grew 2% (constant currency) driven by Labs business strength.
- Adjusted EBITDA $169M with 23% margin; company paid down $52M on term loan in Q3, $175M year-to-date.
- Fiscal 2023 guidance maintained: total revenue $2.88–$3.08B, adjusted EPS $4.85–$5.30.

## SEC filing metadata
- accession: 0001906324-23-000056
- form_type: 8-K
- ticker: QDEL
- cik: 0001906324
- company_name: QuidelOrtho Corp
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000056/0001906324-23-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000056/qdel-20231101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001906324-23-000056
- JSON: https://secwatch.observer/filing/0001906324-23-000056.json
- Plain text: https://secwatch.observer/filing/0001906324-23-000056.txt

## Key facts
- Earnings Releases
  QuidelOrtho Corp reported fiscal year 2023 results: revenue Total revenues (reported) $2.88 - $3.08 billion, EPS Adjusted diluted EPS $4.85 - $5.30. Guidance reaffirmed.
  - Period: fiscal year 2023
  - Revenue: Total revenues (reported) $2.88 - $3.08 billion
  - EPS: Adjusted diluted EPS $4.85 - $5.30
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The Company is maintaining its 2023 financial guidance, provided on August 8, 2023, as follows: Total revenues (reported) $2.88 - $3.08 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000056/0001906324-23-000056-index.htm
- Earnings Releases
  QuidelOrtho Corp reported third quarter ended October 1, 2023 results: revenue Third quarter revenue was $744 million, EPS Third quarter GAAP diluted loss per share was $(0.19); adjusted diluted earnings per share (“EPS”) was $0.90.
  - Period: third quarter ended October 1, 2023
  - Revenue: Third quarter revenue was $744 million
  - EPS: Third quarter GAAP diluted loss per share was $(0.19); adjusted diluted earnings per share (“EPS”) was $0.90
  - Result: reported results
  source text: On November 1, 2023, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its third quarter ended October 1, 2023 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on November 1, 2023 to discuss such results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000056/0001906324-23-000056-index.htm
- Earnings Releases
  QuidelOrtho Corp reported third quarter ended October 1, 2023 results: revenue Third quarter revenue was $744 million, EPS Third quarter GAAP diluted loss per share was $(0.19); adjusted diluted earnings per share (“EPS”) was $0.90.
  - Period: third quarter ended October 1, 2023
  - Revenue: Third quarter revenue was $744 million
  - EPS: Third quarter GAAP diluted loss per share was $(0.19); adjusted diluted earnings per share (“EPS”) was $0.90
  - Result: reported results
  source text: Third quarter revenue was $744 million, as reported, driven by strong respiratory demand and continued strength in non-respiratory businesses
  evidence_url: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000056/0001906324-23-000056-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.